Medical Advisory Board, News, Research, Treatments

Treatment Guidelines for Adults with immune thrombocytopenia in Australia and New Zealand

Review the latest treatment guidelines available for adults living with immune thrombocytopenia in Australia and New Zealand.

These guidelines were last updated in late 2023 due to a number of factors. These include:

  • changes to the Pharmaceutical Benefits Scheme (PBS) reimbursement criteria in Australia and since the original consensus treatment guidelines.1
  • These include:
    • A splenectomy is no longer required to access thrombopoietin receptor agonists (TPO-RAs) such as romplostim and eltrombopag.
    • There are now three TPO-RA available in Australia. These include Romiplostim (NPlate), Eltrombopag (Revolade) and Avatrombopag (Doptelet).
    • Easier to switch between the available TPO-RAs.
    • Rituximab is now unrestricted on the PBS.

Download the updated Consensus Guidelines & update here.

ITP Australia new Zealand Treatment Guidelines


Publish Date: January 1, 2024